Achievement of low disease activity improves long-term structural damage in PsAMarch 23, 2023Psoriatic Arthritis
Gender-based differences in treatment outcomes and persistence with ustekinumab or TNFi in PsAMarch 23, 2023Psoriatic Arthritis
PsA: Baseline disease activity predicts DAPSA response in patients treated with apremilastMarch 9, 2023Psoriatic Arthritis
Baseline cardiovascular risk may influence MACE and malignancy incidences in tofacitinib-treated PsA patientsMarch 9, 2023Psoriatic Arthritis
Circulating microRNA can differentiate between psoriasis and psoriatic arthritisMarch 9, 2023Psoriatic Arthritis
Crude mortality rate doubled in PsA patients during COVID-19 pandemicMarch 9, 2023Psoriatic Arthritis
Real-world evidence on impact of PsA manifestation on patient outcomesMarch 9, 2023Psoriatic Arthritis
Concomitant PsA tied with higher comorbidities and low treatment persistence in psoriasisMarch 9, 2023Psoriatic Arthritis
Diagnostic role of nailfold capillaroscopy for identifying PsA in psoriasis needs further investigationMarch 9, 2023Psoriatic Arthritis
Psoriatic arthritis: An independent risk factor for reduced bone density and fracturesMarch 9, 2023Psoriatic Arthritis
PsA: Guselkumab demonstrates consistent safety profile irrespective of prior TNFi exposureMarch 9, 2023Psoriatic Arthritis
